Aurobindo Pharma Subsidiary Lannett Launches First US Inhalation Product in $908M Market
Aurobindo Pharma's subsidiary, Lannett Company LLC, has commercialised a generic version of Advair Diskus in the United States. This represents the company's entry into the complex US inhalation market, targeting a therapeutic area valued at nearly $1 billion.
Glenmark Pharma Launches Calcium Gluconate Injection in US Market Worth $69.9 Million
Glenmark Pharmaceuticals Inc., USA has introduced Calcium Gluconate Injection USP in multiple dosage presentations for the United States market. This launch aims to strengthen the company's presence in the U.S. hospital sector by providing bioequivalent therapeutic alternatives to existing critical care medications.
Granules India Secures Sole First-to-File Status for Sodium Oxybate Generic in US
Granules India has achieved Sole First-to-File status for its Sodium Oxybate Extended-Release ANDA, a generic equivalent of LUMRYZ. This regulatory milestone provides a strategic advantage in the US complex generics market and potentially grants the company marketing exclusivity.
Glenmark Pharmaceuticals Launches Lacosamide Injection in USA Targeting $15.2M Market
Glenmark Pharmaceuticals Inc., USA, has announced the commercial launch of Lacosamide Injection USP, a generic version of Vimpat®. This move expands the company's injectable portfolio in the United States, targeting a market with approximately $15.2 million in annual sales as of April 2026.
Aurionpro Solutions Bags Largest US Fintech Order Worth USD 33 Million Over Three Years
Aurionpro Solutions Ltd has announced its largest-ever US market win, a three-year fintech contract valued at USD 33 million (approximately ₹316.80 Crore). The project involves delivering advanced AI-led technology solutions and platform enhancements for a leading digital insurance payments provider.